We are live on ! Find out more
RJA

Raymond James & Associates Portfolio holdings

AUM $164B
1-Year Est. Return 33.91%
This Fund
S&P 500
This Quarter Est. Return
+2.67%
1 Year Est. Return
+33.91%
3 Year Est. Return
+39.99%
5 Year Est. Return
+107.66%
10 Year Est. Return
+221.81%
AUM
$46.3B
AUM Growth
+$3.2B
Cap. Flow
+$2.34B
Cap. Flow %
5.07%
Top 10 Hldgs %
17.9%
Holding
3,541
New
248
Increased
1,836
Reduced
1,143
Closed
207

Sector Composition

Rank Sector Weight
1 Technology 9.28%
2 Healthcare 9.23%
3 Financials 8.81%
4 Industrials 6.85%
5 Communication Services 6.16%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
RF icon
426
Regions Financial
RF
$26.8B
$20.6M 0.04%
1,405,750
+435,625
+45% +$6.13M
WRK
427
DELISTED
WestRock Company
WRK
$20.6M 0.04%
363,174
+38,537
+12% +$2.09M
XSD icon
428
State Street SPDR S&P Semiconductor ETF
XSD
$2.77B
$20.5M 0.04%
333,186
-4,078
-1% -$252K
TU icon
429
Telus
TU
$14.9B
$20.5M 0.04%
1,189,576
+35,210
+3% +$591K
XMLV icon
430
Invesco S&P MidCap Low Volatility ETF
XMLV
$750M
$20.5M 0.04%
474,559
+54,523
+13% +$2.34M
LH icon
431
Labcorp
LH
$25B
$20.5M 0.04%
154,592
+26,852
+21% +$3.29M
PRU icon
432
Prudential Financial
PRU
$42.8B
$20.5M 0.04%
189,287
+2,296
+1% +$244K
EIX icon
433
Edison International
EIX
$27.5B
$20.5M 0.04%
261,651
+8,132
+3% +$651K
XPO icon
434
XPO
XPO
$23.1B
$20.2M 0.04%
905,428
+192,462
+27% +$3.6M
ADI icon
435
Analog Devices
ADI
$177B
$20.1M 0.04%
258,189
-95,253
-27% -$7.57M
MRSH
436
Marsh
MRSH
$92.1B
$20M 0.04%
256,022
-15,145
-6% -$1.14M
DOC
437
DELISTED
PHYSICIANS REALTY TRUST
DOC
$20M 0.04%
990,646
+615,834
+164% +$12.5M
IEX icon
438
IDEX
IEX
$17.2B
$19.9M 0.04%
175,877
+9,000
+5% +$946K
HSIC icon
439
Henry Schein
HSIC
$9.81B
$19.8M 0.04%
275,658
+429
+0.2% +$29.9K
BIP icon
440
Brookfield Infrastructure Partners
BIP
$18.6B
$19.5M 0.04%
799,378
+31,109
+4% +$736K
HI
441
DELISTED
Hillenbrand
HI
$19.4M 0.04%
538,654
-3,440
-0.6% -$125K
FITB
442
Fifth Third Bancorp
FITB
$51.6B
$19.4M 0.04%
745,607
+23,032
+3% +$569K
BERY
443
DELISTED
Berry Global Group, Inc.
BERY
$19.3M 0.04%
368,245
+5,606
+2% +$280K
EW icon
444
Edwards Lifesciences
EW
$51B
$19.2M 0.04%
486,243
+61,878
+15% +$2.26M
NSC icon
445
Norfolk Southern
NSC
$75.3B
$19.1M 0.04%
157,336
+2,749
+2% +$323K
HSBC icon
446
HSBC
HSBC
$369B
$19.1M 0.04%
451,521
+6,695
+2% +$260K
NFX
447
DELISTED
Newfield Exploration
NFX
$19.1M 0.04%
671,786
+157,295
+31% +$5.18M
KRE icon
448
State Street SPDR S&P Regional Banking ETF
KRE
$4.7B
$19.1M 0.04%
346,908
-70,267
-17% -$3.78M
VXF icon
449
Vanguard Extended Market ETF
VXF
$30.8B
$18.9M 0.04%
184,796
+14,991
+9% +$1.51M
DAR icon
450
Darling Ingredients
DAR
$9.47B
$18.9M 0.04%
1,200,559
-3,689
-0.3% -$57K

Similar funds

Raymond James & Associates's Q2 2017 Portfolio in Review

As of Q2 2017, Raymond James & Associates held 3,541 positions worth $46.3B, up 7.4% from $43.1B the previous quarter. Its ten largest holdings account for 18% of the portfolio.

Raymond James & Associates deployed $2.34B of net new capital in Q2 2017, opening 248 new positions and adding to 1,836 existing holdings. Its largest new stake was DXC Technology: 324,843 shares worth $21.6M.

By sector, the portfolio is most concentrated in Technology at 9.3% of assets, down from 9.6% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Novartis, an estimated $53.7M trimmed.

  • Raymond James & Associates's largest Q2 2017 buy was DXC Technology: 324,843 shares worth $21.6M.
  • Raymond James & Associates added most to Vanguard S&P 500 ETF in Q2 2017, an estimated $308M increase.
  • Raymond James & Associates's biggest Q2 2017 reduction was Novartis, cutting an estimated $53.7M.
  • Raymond James & Associates fully exited Energy Transfer Partners L.p. in Q2 2017, selling an estimated $24.9M.
  • Raymond James & Associates's ten largest holdings make up 18% of its $46.3B portfolio in Q2 2017.
  • Raymond James & Associates opened 248 new positions and closed 207 in Q2 2017.
  • Raymond James & Associates's portfolio value rose 7.4% quarter-over-quarter to $46.3B.

Based on Raymond James & Associates's 13F filing for Q2 2017, filed 14 Aug 2017.